Marcin S.
- Country
- Poland
- Department
- Oncology-Hematology
Research Overview
- A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer
- Phase III Randomized Double-Blind Trial of Tiragolumab and Atezolizumab Versus Placebo and Atezolizumab in Resected Stage IIB-IIIB PD-L1 Positive NSCLC
- Phase I/II Study on Safety, Tolerability, and Immunogenicity of PDC*lung01 with or without Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 78 of 269 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of non-small cell lung cancer (NSCLC), with particular emphasis on developing innovative therapeutic approaches for patients who have undergone previous treatments.
- Advanced lung cancer therapies
- Novel treatment combinations
- Cancer immunotherapy approaches
The investigator explores various therapeutic modalities including cancer vaccines and targeted antibody-drug conjugates in the treatment of lung cancer.
Immunotherapy Research
A significant focus of the investigator's work involves cancer immunotherapy, particularly in combination with conventional treatments for lung cancer patients.
- Vaccine-based immunotherapy
- Anti-PD-1 therapy combinations
- Immunological response assessment
The research encompasses evaluation of immune response patterns and therapeutic efficacy in lung cancer treatment protocols.
Treatment Optimization
The investigator works on optimizing treatment strategies for lung cancer patients, with particular attention to those who have received prior therapy.
- Comparative treatment efficacy
- Safety profile assessment
- Response rate evaluation
Research includes investigation of novel therapeutic agents compared to established treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.